Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

High Blood Pressure (Hypertension): Clinical Breakdown: Pathophysiology, Blood Pressure Classification, Primary vs. Secondary Etiology, Target Organ Damage, and Therapeutic Management

A cardiovascular pathology reference on the determinants of blood pressure, the full classification table from normal to hypertensive crisis, primary versus secondary causes, target organ damage and the main therapeutic classes.

Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026

Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.

What we found that needs correcting

  • This is the most technically accurate of the three briefs. The classification table, the BP = CO x SVR framing, the primary and secondary split and the target organ list are all correct. The notes below are additions rather than corrections, and one proportion that current evidence has revised.
  • The share attributed to primary aldosteronism understates it. It is listed among secondary causes, which is right, and screening studies now find it in a meaningful proportion of all hypertension and a considerably larger proportion of resistant hypertension. Most people with it have normal potassium, which is why the classic teaching about hypokalaemia has led to it being missed. It carries higher cardiovascular and kidney risk than equivalent primary hypertension and has specific treatment, surgical for a one-sided adenoma or a mineralocorticoid receptor antagonist otherwise. Screening is a simple aldosterone-to-renin ratio and is rarely done.
  • The classification table is correct and would benefit from two notes for readers interpreting their own numbers: when the systolic and diastolic fall in different categories, the higher category applies; and isolated systolic hypertension, a raised top number with a normal bottom number, is the commonest pattern after about 60 and is treated rather than dismissed.
  • Out-of-office thresholds are missing and matter for anyone using a home monitor. Home and ambulatory readings use lower numbers than clinic readings: a daytime ambulatory average of 130/80, a 24-hour average of 125/75, and a night-time average of 110/65. Night-time pressure is the strongest single predictor of cardiovascular outcome and only ambulatory monitoring measures it. White-coat and masked hypertension both follow from this, and masked hypertension, normal in clinic and high outside it, carries risk comparable to sustained hypertension and is missed entirely by clinic measurement.
  • The hypertensive crisis row should be split, because the distinction determines what happens next. Hypertensive emergency means those readings with evidence of acute end-organ damage, including chest pain, breathlessness, neurological change or papilloedema, and requires immediate treatment. Hypertensive urgency means the same readings without such features, and is managed by rechecking and prompt outpatient adjustment. Rapidly lowering pressure in an asymptomatic person can cause harm.
  • The management section lists classes without the practical architecture. Combining two classes at low dose lowers pressure roughly five times more than doubling a single drug, which is why most people need more than one agent and why single-pill combinations matter. Beta-blockers are no longer first-line for uncomplicated hypertension because they prevent stroke less effectively, and are reserved for a coexisting indication. Thiazide-like agents such as chlorthalidone and indapamide are preferred over hydrochlorothiazide in several guidelines. Spironolactone is the most effective fourth drug in resistant hypertension, as shown in PATHWAY-2.
  • Treatment targets are absent. Current US guidance sets a general target below 130/80. SPRINT found that a systolic target below 120 reduced cardiovascular events and deaths in high-risk adults without diabetes, at the cost of more hypotension, syncope and kidney function changes, and it measured blood pressure in a way that yields lower numbers than typical clinic practice. In older and frailer adults the balance shifts and standing blood pressure should be checked.
  • Two pathophysiological points would strengthen section 1: the kidney sets long-term pressure through pressure natriuresis, with the relationship shifted in hypertension so that a higher pressure is required to excrete the same sodium load, which is why sodium handling underlies so much of this; and arterial stiffening with age raises systolic while lowering diastolic, widening pulse pressure and producing isolated systolic hypertension.
  • One addition to target organ damage: left ventricular hypertrophy regresses with sustained control and that regression is associated with better outcomes, which is a rare example of reversible damage worth telling patients about. Albuminuria is the earliest detectable kidney sign and precedes changes in filtration rate, and ACE inhibitors and ARBs protect the kidney beyond their pressure effect when it is present.
  • Everything else in the brief is accurate: hypertension as chronically elevated systemic arterial pressure, the silent killer framing, increased afterload and endothelial mechanical stress raising risk of myocardial infarction, stroke, heart failure and chronic kidney disease; BP as the product of cardiac output and systemic vascular resistance with chronic hypertension driven by raised peripheral resistance and neurohormonal dysregulation; the full classification table; primary hypertension at 90 to 95 percent arising from genetics, sympathetic overactivity, RAAS dysfunction, endothelial stiffness and environment; secondary hypertension at 5 to 10 percent from renovascular disease, hyperaldosteronism, sleep apnoea, chronic kidney disease and endocrine causes; target organ damage including left ventricular hypertrophy, coronary disease, ischaemic and haemorrhagic stroke, hypertensive nephrosclerosis and retinopathy; and combined lifestyle and pharmacological management.

Download the PDF

All source documents